2 results match your criteria: "The School of Pharmaceutical Sciences in Central South University.[Affiliation]"
SM-1, a novel PAC-1 derivative, activates procaspase-3 and causes cancer cell apoptosis.
Cancer Chemother Pharmacol
September 2016
The School of Pharmaceutical Sciences in Central South University, 172 Tongzipo Road, Yuelu District, Changsha, 410013, Hunan, China.
Article Synopsis
- The study focused on synthesizing and evaluating 7 new derivatives of PAC-1, with SM-1 emerging as the most effective in activating procaspase-3 and showing favorable pharmacokinetics.
- In vitro and in vivo tests revealed that SM-1 significantly enhanced caspase-3 activity, leading to increased cancer cell apoptosis while effectively reducing tumor size in mouse models.
- Preliminary safety tests indicated that SM-1 has a relatively low toxicity profile, making it a promising candidate for further evaluation as an antitumor treatment.
Hypothesis: Simotinib hydrochloride (SIM6802), which is a new epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is often prescribed for cancer patients with comorbidities and has serious adverse effects on gastrointestinal physiology. The drug-drug interactions (DDIs) between simotinib and other drugs in combination and the underlying mechanism of its gastrointestinal toxicity remain unclear. We hypothesized that the DDIs and the gastrointestinal toxicity of simotinib were related to its effects on the permeability of the intestine.
View Article and Find Full Text PDF